Validating Targeted Breast Cancer Therapies for Clinical Practice

MammaPrint® and the I-SPY I and I-SPY II Breast Cancer Clinical Trials

(CALGB 150007/150012 & ACRIN 6657)

Agendia’s MammaPrint signature and its microarray technology are integral components of biomarker analysis and molecular prediction in the landmark National Cancer Institute supported I-SPY I and I-SPY II breast cancer clinical trials which focus on the prediction of therapeutic response in the neoadjuvant setting. The utilization of MammaPrint and Agendia’s whole-genome, microarray platform are anticipated to assist in rapid, focused development of oncologic therapies paired with biomarkers.

Key Objectives of I-SPY breast cancer trials for which the MammaPrint whole-genome microarray is utilized:

  • I-SPY I evaluated biomarkers and imaging for predicting response to standard neoadjuvant chemotherapy
  • I-SPY II will evaluate Phase 2 drugs in combination with standard chemotherapy in a neoadjuvant setting
  • I-SPY II will use biomarkers to stratify patients based on their predicted likelihood of response to treatment

For additional information on I-SPY clinical trial please visit: I-SPY Breast Cancer Clinical Trial or visit the National Cancer Institute's page: I-SPY  Breast Cancer Clinical Trial at cancer.gov

To inquire about participation in the I-SPY trial, please contact Agendia Clinical Trials.